4/A//SEC Filing
CZIRR JAMES C 4/A
Accession 0001493152-25-026587
CIK 0001133416other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 1:21 PM ET
Size
11.6 KB
Accession
0001493152-25-026587
Insider Transaction Report
Form 4/AAmended
10X Fund, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-12-02$5.47/sh−30,000$164,100→ 5,802,207 total - Sale
Common Stock
2025-12-03$5.73/sh−132,069$756,755→ 5,670,138 total
10X Capital Management, LLC
10% Owner
Transactions
- Sale
Common Stock
2025-12-02$5.47/sh−30,000$164,100→ 5,802,207 total - Sale
Common Stock
2025-12-03$5.73/sh−132,069$756,755→ 5,670,138 total
CZIRR JAMES C
Director10% Owner
Transactions
- Sale
Common Stock
2025-12-02$5.47/sh−30,000$164,100→ 5,802,207 total - Sale
Common Stock
2025-12-03$5.73/sh−132,069$756,755→ 5,670,138 total
Footnotes (3)
- [F1]10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F2]The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0001260641
Filing Metadata
- Form type
- 4/A
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 1:21 PM ET
- Size
- 11.6 KB